Trexquant Investment LP Has $4.39 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Trexquant Investment LP reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 47.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,585 shares of the biopharmaceutical company’s stock after selling 46,964 shares during the period. Trexquant Investment LP’s holdings in Intra-Cellular Therapies were worth $4,392,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the fourth quarter valued at about $96,000. Wilmington Savings Fund Society FSB acquired a new position in Intra-Cellular Therapies in the 3rd quarter valued at approximately $97,000. Quarry LP increased its holdings in Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 1,300 shares during the period. Finally, Barlow Wealth Partners Inc. bought a new position in shares of Intra-Cellular Therapies during the 4th quarter worth about $184,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $131.87 on Friday. The stock has a 50-day simple moving average of $129.62 and a 200 day simple moving average of $101.61. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98. The company has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday. Finally, Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.